Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Institut de Recherches Internationales Servier (France)
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Phase I study of oral administration of S 78454 in association with doxorubicin in patients with solid tumour
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
Not provided at time of registration and not expected to be available in the future
Country
Canada
,
Denmark
,
Estonia
,
Finland
,
Hungary
,
Sweden
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
S 05985 combination versus AT1-Receptor Blocker/thiazide: a comparison of blood pressure lowering - efficacy and safety
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Early effect of agomelatine on general interest in outpatients suffering major depressive disorder
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
The efficacy and safety of strontium ranelate versus placebo in the treatment of knee osteoarthritis
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
SOTI and TROPOS phase III studies open-label extension. The long term efficacy and long term safety assessment of a five-year oral administration of strontium ranelate in osteoporotic postmenopausal women having participated either in Spinal Osteoporosis Therapeutic Intervention "SOTI" study or TReatment Of Peripheral OSteoporosis "TROPOS" study. A five-year multicentric multinational open study with strontium ranelate
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety Disorder
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for eight weeks in out-patients with severe major depressive disorder: a randomised double-blind, parallel groups, international study versus selective serotonin reuptake inhibitor (SSRI) with a double-blind extension period of 16 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
An efficacy and safety study comparing the fixed combination of two antihypertensive agents, indapamide and amlodipine in a single-pill, to the same drugs given separately, in patients with mild to moderate uncontrolled essential hypertension
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
Next